Edwards Lifesciences Corp (EW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 766,700 | 492,000 | 249,700 | 722,200 | 715,200 |
| Depreciation Amortization | 65,400 | 42,300 | 20,600 | 77,400 | 57,500 |
| Income taxes - deferred | 9,500 | 12,900 | 5,800 | -27,300 | 29,800 |
| Accounts receivable | -70,300 | -89,200 | -45,800 | -28,700 | -300 |
| Other Working Capital | -67,900 | -156,600 | -324,800 | -222,700 | -235,000 |
| Other Operating Activity | 76,600 | 41,300 | 96,000 | 405,800 | 66,600 |
| Operating Cash Flow | $780,000 | $342,700 | $1,500 | $926,700 | $633,800 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | N/A | -5,400 | -1,900 | N/A | N/A |
| PPE Investments | -182,900 | -106,800 | -42,200 | -238,700 | -181,100 |
| Net Acquisitions | -135,200 | -135,200 | -35,000 | N/A | N/A |
| Purchase Of Investment | -125,000 | -105,400 | -31,300 | -459,300 | -305,300 |
| Sale Of Investment | 328,300 | 240,800 | 76,100 | 801,300 | 581,200 |
| Purchase Sale Intangibles | -24,000 | -24,000 | -16,800 | -3,000 | -3,000 |
| Other Investing Activity | -35,700 | -25,800 | -15,200 | -26,600 | -23,800 |
| Investing Cash Flow | $-150,500 | $-137,800 | $-49,500 | $76,700 | $71,000 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 12,000 | 9,700 | 3,700 | 688,000 | 686,400 |
| Debt Repayment | N/A | -20,200 | -4,000 | -1,125,300 | -524,100 |
| Common Stock Issued | 125,500 | 86,500 | 45,000 | 147,000 | 119,300 |
| Common Stock Repurchased | -263,300 | -262,000 | -5,700 | -795,500 | -523,500 |
| Other Financing Activity | -26,800 | -1,000 | 5,400 | -15,400 | -14,600 |
| Financing Cash Flow | $-152,600 | $-187,000 | $44,400 | $-1,101,200 | $-256,500 |
| Exchange Rate Effect | -4,400 | -5,200 | -1,300 | -6,500 | -5,300 |
| Beginning Cash Position | 714,100 | 714,100 | 714,100 | 820,200 | 818,300 |
| End Cash Position | 1,186,600 | 726,800 | 709,200 | 715,900 | 1,261,300 |
| Net Cash Flow | $472,500 | $12,700 | $-4,900 | $-104,300 | $443,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 780,000 | 342,700 | 1,500 | 926,700 | 633,800 |
| Capital Expenditure | -182,900 | -106,800 | -42,200 | -238,700 | -181,100 |
| Free Cash Flow | 597,100 | 235,900 | -40,700 | 688,000 | 452,700 |